A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial

Table 2 Flowchart (diagnostic procedures and run-in treatment)

Baseline	Day 1	Day 8	Day 14		Day 56
PET-CT	Cetuximab	Cetuximab	PET-CT	Folfiri-Cetuximab	CT

ISSN: 1471-2407